Prognostic effects of calcium channel blockers on cardiac events, stroke and end-stage renal disease in patients with angina pectoris: Retrospective comparative study of benidipine, diltiazem and nifedipine

Arzneimittel-Forschung/Drug Research

Volumn 58, Issue 9, 2008, Pages 435-440

  Arioka, Ichiro ^a,b   Dohi, Shunichiro ^a   Dohi, Shizuyuki ^a   Sakai, Kenya ^a  

^a Dohi Hospital   (Japan)

^b Dohi Hospital   (Japan)

Author keywords

Angina pectoris; Benidipine; Calcium channel blockers, cardiovascular events, prognostic effect; CAS 21829 25 4; CAS 33286 22 5; CAS 91599 74 5; Coniel ; Diltiazem; Nifedipine

Indexed keywords

BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; NIFEDIPINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; DRUG EFFECT; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INCIDENCE; JAPANESE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGNOSIS; RETROSPECTIVE STUDY; STROKE;

EID: 53649098467     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296535     Document Type: Article

References (27)

1. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, et al. Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res. 2004;27:181-191.
2. Pristipino C, Beltrame JF, Finocchiaro ML, Hattori R, Fujita M, Mongiardo R, et al. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation. 2000;101:1102-1108.
3. Shimokawa H, Nagasawa K, Irie T, Egashira S, Egashira K, Sagara T, et al. Clinical characteristics and long-term prognosis of patients with variant angina. A comparative study between western and Japanese populations. Int J Cardiol. 1988;18:331-349.
4. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA. 1983;250:2814-2819.
5. Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol. 2004;93:969-973.
6. The Israeli Sprint Study Group. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT): A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J. 1988;9:354-364.
7. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995; 274: 620-625.
8. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
9. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364:849-857.
10. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102:1503-1510.
11. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res. 2006;29:S1-S105.
12. The Japanese Circulation Society, The Japanese College of Cardiology, The Japanese Association for Thoracic Surgery, The Japanese Society for Cardiovascular Surgery. Guideline for Surgical and Interventional Treatment of Valvular Heart Disease. Circ J. 2002;66(S4):1325-1350.
13. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation. 1998;97:576-580.
14. Matsubara M, Yao K, Hasegawa K. Benidipine, a dihydropyridine-calcium channel blocker, inhibits lysophosphatidylcholine-induced endothelial injury via stimulation of nitric oxide release. Pharmacol Res. 2006;53:35-43.
15. Kitakaze M, Node K, Minamino T, Asanuma H, Kuzuya T, Hori M. A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. J Am Coll Cardiol. 1999;33:242-249.
16. Wang N, Minatoguchi S, Chen XH, Arai M, Uno Y, Lu C, et al. Benidipine reduces myocardial infarct size involving reduction of hydroxyl radicals and production of protein kinase C-dependent nitric oxide in rabbits. J Cardiovasc Pharmacol. 2004;43:747-757.
17. Karasawa A, Ikeda J, Yamada K, Kubo K, Oka T, Nakamizo N. Antihypertensive effects of the new calcium antagonist benidipine hydrochloride in conscious, renal-hypertensive dogs. Arzneimittel-Forschung (Drug Research). 1988;38:1695-1697.
18. Nomura M, Nakaya Y, Uemura E, Sawa Y, Iga A, Kageyama N, et al. Effects of benidipine hydrochloride on autonomic nervous activity in hypertensive patients with high- and low-salt diets. Arzneimittel-Forschung (Drug Research). 2003;53:314-320.
19. Shimamoto H, Shimamoto Y. Benidipine counteracts sodium-induced alterations in systemic and regional hemodynamics. Blood Press. 1997;6:18-23.
20. Yao K, Ina Y, Sonoda R, Nagashima K, Ohmori K, Ohno T. Protective effects of benidipine on hydrogen peroxide-induced injury in rat isolated hearts. J Pharm Pharmacol. 2003;55:109-114.
21. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535
22. Ikeda J, Yao K, Matsubara M. Effects of benidipine, a long-lasting dihydropyridine-Ca2+ channel blocker, on cerebral blood flow autoregulation in spontaneously hypertensive rats. Biol Pharm Bull. 2006;29:2222-2225.
23. Kitayama J, Kitazono T, Ooboshi H, Takada J, Fujishima M, Ibayashi S. Long-term effects of benidipine on cerebral vasoreactivity in hypertensive rats. Eur J Pharmacol. 2002;438:153-158.
24. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
25. Inoue S, Tomino Y. Effects of calcium antagonists in hypertensive patients with renal dysfunction: a prospective, randomized, parallel trial comparing benidipine and nifedipine. Nephrology (Carlton). 2004;9:265-271.
26. Akizuki O, Inayoshi A, Kitayama T, Yao K, Shirakura S, Sasaki K, et al. Blockade of T-type voltage-dependent Ca(2+) channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol. 2008;584:424-434.
27. Morikawa T, Okumura M, Konishi Y, Okada N, Imanishi M. Effects of benidipine on glomerular hemodynamics and proteinuria in patients with nondiabetic nephropathy. Hypertens Res. 2002;25:571-576.